Cargando…

Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway

PURPOSE: Sepsis is an aggressive and life-threatening organ dysfunction induced by infection. Excessive inflammation and coagulation contribute to the negative outcomes for sepsis, resulting in high morbidity and mortality. In this study, we explored whether Eupatilin could alleviate lung injury, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yilun, Li, Ding, Huang, Yueyue, Sun, Yuanyuan, Zhou, Hongmin, Ye, Fanrong, Yang, Hongjing, Xu, Tingting, Quan, Shichao, Pan, Jingye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013575/
https://www.ncbi.nlm.nih.gov/pubmed/36926276
http://dx.doi.org/10.2147/JIR.S393850
_version_ 1784906815742410752
author Lu, Yilun
Li, Ding
Huang, Yueyue
Sun, Yuanyuan
Zhou, Hongmin
Ye, Fanrong
Yang, Hongjing
Xu, Tingting
Quan, Shichao
Pan, Jingye
author_facet Lu, Yilun
Li, Ding
Huang, Yueyue
Sun, Yuanyuan
Zhou, Hongmin
Ye, Fanrong
Yang, Hongjing
Xu, Tingting
Quan, Shichao
Pan, Jingye
author_sort Lu, Yilun
collection PubMed
description PURPOSE: Sepsis is an aggressive and life-threatening organ dysfunction induced by infection. Excessive inflammation and coagulation contribute to the negative outcomes for sepsis, resulting in high morbidity and mortality. In this study, we explored whether Eupatilin could alleviate lung injury, reduce inflammation and coagulation during sepsis. METHODS: We constructed an in vitro sepsis model by stimulating RAW264.7 cells with 1 μg/mL lipopolysaccharide (LPS) for 6 hours. The cells were divided into control group, LPS group, LPS+ Eupatilin (Eup) group, and Eup group to detect their cell activity and inflammatory cytokines and coagulation factor levels. Cells in LPS+Eup and Eup group were pretreated with Eupatilin (10μM) for 2 hours. In vivo, mice were divided into sham operation group, cecal ligation and puncture (CLP) group and Eup group. Mice in the CLP and Eup groups were pretreated with Eupatilin (10mg/kg) for 2 hours by gavage. Lung tissue and plasma were collected and inflammatory cytokines, coagulation factors and signaling were measured. RESULTS: In vitro, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and tissue factor (TF) expression in LPS-stimulated RAW264.7 cells was downregulated by Eupatilin (10μM). Furthermore, Eupatilin inhibited phosphorylation of the JAK2/STAT3 signaling pathway and suppressed p-STAT3 nuclear translocation. In vivo, Eupatilin increased the survival rate of the mice. In septic mice, plasma concentrations of TNF-α, IL-1β and IL-6, as well as TF, plasminogen activator inhibitor 1 (PAI-1), D-dimer, thrombin-antithrombin complex (TAT) and fibrinogen were improved by Eupatilin. Moreover, Eupatilin alleviated lung injury by improving the expression of inflammatory cytokines and TF, fibrin deposition and macrophage infiltration in lung tissue. CONCLUSION: Our results revealed that Eupatilin may modulate inflammation and coagulation indicators as well as improve lung injury in sepsis via the JAK2/STAT3 signaling pathway.
format Online
Article
Text
id pubmed-10013575
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100135752023-03-15 Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway Lu, Yilun Li, Ding Huang, Yueyue Sun, Yuanyuan Zhou, Hongmin Ye, Fanrong Yang, Hongjing Xu, Tingting Quan, Shichao Pan, Jingye J Inflamm Res Original Research PURPOSE: Sepsis is an aggressive and life-threatening organ dysfunction induced by infection. Excessive inflammation and coagulation contribute to the negative outcomes for sepsis, resulting in high morbidity and mortality. In this study, we explored whether Eupatilin could alleviate lung injury, reduce inflammation and coagulation during sepsis. METHODS: We constructed an in vitro sepsis model by stimulating RAW264.7 cells with 1 μg/mL lipopolysaccharide (LPS) for 6 hours. The cells were divided into control group, LPS group, LPS+ Eupatilin (Eup) group, and Eup group to detect their cell activity and inflammatory cytokines and coagulation factor levels. Cells in LPS+Eup and Eup group were pretreated with Eupatilin (10μM) for 2 hours. In vivo, mice were divided into sham operation group, cecal ligation and puncture (CLP) group and Eup group. Mice in the CLP and Eup groups were pretreated with Eupatilin (10mg/kg) for 2 hours by gavage. Lung tissue and plasma were collected and inflammatory cytokines, coagulation factors and signaling were measured. RESULTS: In vitro, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and tissue factor (TF) expression in LPS-stimulated RAW264.7 cells was downregulated by Eupatilin (10μM). Furthermore, Eupatilin inhibited phosphorylation of the JAK2/STAT3 signaling pathway and suppressed p-STAT3 nuclear translocation. In vivo, Eupatilin increased the survival rate of the mice. In septic mice, plasma concentrations of TNF-α, IL-1β and IL-6, as well as TF, plasminogen activator inhibitor 1 (PAI-1), D-dimer, thrombin-antithrombin complex (TAT) and fibrinogen were improved by Eupatilin. Moreover, Eupatilin alleviated lung injury by improving the expression of inflammatory cytokines and TF, fibrin deposition and macrophage infiltration in lung tissue. CONCLUSION: Our results revealed that Eupatilin may modulate inflammation and coagulation indicators as well as improve lung injury in sepsis via the JAK2/STAT3 signaling pathway. Dove 2023-03-10 /pmc/articles/PMC10013575/ /pubmed/36926276 http://dx.doi.org/10.2147/JIR.S393850 Text en © 2023 Lu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lu, Yilun
Li, Ding
Huang, Yueyue
Sun, Yuanyuan
Zhou, Hongmin
Ye, Fanrong
Yang, Hongjing
Xu, Tingting
Quan, Shichao
Pan, Jingye
Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway
title Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway
title_full Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway
title_fullStr Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway
title_full_unstemmed Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway
title_short Pretreatment with Eupatilin Attenuates Inflammation and Coagulation in Sepsis by Suppressing JAK2/STAT3 Signaling Pathway
title_sort pretreatment with eupatilin attenuates inflammation and coagulation in sepsis by suppressing jak2/stat3 signaling pathway
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013575/
https://www.ncbi.nlm.nih.gov/pubmed/36926276
http://dx.doi.org/10.2147/JIR.S393850
work_keys_str_mv AT luyilun pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway
AT liding pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway
AT huangyueyue pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway
AT sunyuanyuan pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway
AT zhouhongmin pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway
AT yefanrong pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway
AT yanghongjing pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway
AT xutingting pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway
AT quanshichao pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway
AT panjingye pretreatmentwitheupatilinattenuatesinflammationandcoagulationinsepsisbysuppressingjak2stat3signalingpathway